The Journal of Clinical Psychiatry
July 20, 2017
Chittaranjan Andrade
179 citations
BACKGROUND: Ketamine, administered in subanesthetic doses, is an effective off-label treatment for severe and even treatment-refractory depression; however, despite dozens of studies across nearly 2 decades of research, there is no definitive guidance on matters related to core practice issues. METHODS: This article presents a qualitative review and summary about what is known about ketamine...
July 1, 2017
B. Pradhan, Irving W. Wainer, Ruin Moaddel et al.
Background and objectives: Trauma memories lay at the core in etiopathogenesis of post-traumatic stress disorder (PTSD). Using pharmacological and cognitive behavioral treatments that specifically target trauma memories can improve the outcome. Ketamine has been shown to rapidly improve symptoms in PTSD and comorbid depression, but unfortunately these effects are short-lived. Trauma...
American Journal of Psychiatry
July 1, 2017
S. T. Wilkinson, Mesut Toprak, Mason S. Turner et al.
TO THE EDITOR: Since 2000, several small randomized controlled trials have demonstrated that ketamine has potent and rapid-acting antidepressant effects in patients with treatment-resistant depression (1). Despite a lack of longterm data or Food and Drug Administration indication, many community providers and academic centers have begun offering ketamine treatment to patients with major...
Neurotoxicity Research
July 1, 2017
Jana Ruda-Kucerova, Zuzana Babinska, Tibor Stark et al.
26 citations
Ketamine may prove to be a potential candidate in treating the widespread drug addiction/substance abuse epidemic among patients with schizophrenia. Clinical studies have shown ketamine to reduce cocaine and heroin cravings. However, the use of ketamine remains controversial as it may exacerbate the symptoms of schizophrenia. Therefore, the aim of this study is to characterize the effects of...
Frontiers in Cellular Neuroscience
June 28, 2017
Malwina Lisek, Bozena Ferenc, Maciej Studzian et al.
Ketamine causes psychotic episodes and is often used as pharmacological model of psychotic-like behavior in animals. There is increasing evidence that molecular mechanism of its action is more complicated than just N-methyl-D-aspartic acid (NMDA) receptor antagonism and involves interaction with the components of calcium homeostatic machinery, in particular plasma membrane calcium pump (PMCA)....
Cochrane Database of Systematic Reviews
June 28, 2017
Rae Frances Bell, Christopher Eccleston, Eija Kalso
246 citations
BACKGROUND: This is an update of a review first published in 2003 and updated in 2012.Ketamine is a commonly used anaesthetic agent, and in subanaesthetic doses is also given as an adjuvant to opioids for the treatment of refractory cancer pain, when opioids alone or in combination with appropriate adjuvant analgesics prove to be ineffective. Ketamine is known to have psychomimetic (including...
The Journal of Clinical Psychiatry
June 27, 2017
Chittaranjan Andrade
80 citations
Ketamine is a racemic mixture of the enantiomers R-ketamine and S-ketamine (esketamine). S-ketamine has greater analgesic and anesthetic effects than R-ketamine and is less likely to cause psychotomimetic and other adverse effects. There is therefore an emerging interest favoring the use of S-ketamine over racemic ketamine when the drug is used for analgesia or anesthesia. This article examines...
Brain and Behavior
June 23, 2017
Yinghong Jiang, Yiqiang Wang, Xiaoran Sun et al.
63 citations
Abstract Objective This research was aimed to evaluate the behaviors of short‐ or long‐term antidepressant effects of ketamine in rats exposed to chronic unpredictable stress (CUS). Background Ketamine, a glutamate noncompetitive NMDA receptor antagonist, regulates excitatory amino acid functions, such as anxiety disorders and major depression, and plays an important role in synaptic plasticity...
ACS Chemical Neuroscience
June 21, 2017
Marshall Tyler, Harmony B Yourish, Dawn F. Ionescu et al.
Ketamine, a molecule of many faces, has contributed immeasurably to numerous realms of clinical practice and scientific inquiry. From anesthesia and analgesia to depression and schizophrenia, it continues to shed light on the molecular underpinnings of pain, consciousness, and the pathophysiology of neuropsychiatric disorders. In particular, research on ketamine's mechanism of action is...
Scientific Reports
June 5, 2017
Ze-Min Xie, Xingming Wang, Ning Xu et al.
69 citations
Although pain is frequently accompanied with depression, little is known about the risk factors contributing to individual differences to the comorbidity of pain and depression. In this study, we examined whether cytokines and brain-derived neurotrophic factor (BDNF) might contribute to the individual differences in the development of neuropathic pain-induced depression. Rats were randomly...